The estimated Net Worth of Frank T Watkins is at least 22.5 百万$ dollars as of 6 March 2024. Frank Watkins owns over 2,000 units of Shockwave Medical stock worth over 2,186,587$ and over the last 6 years Frank sold SWAV stock worth over 20,305,230$.
Frank has made over 42 trades of the Shockwave Medical stock since 2020, according to the Form 4 filled with the SEC. Most recently Frank exercised 2,000 units of SWAV stock worth 6,840$ on 6 March 2024.
The largest trade Frank's ever made was selling 20,000 units of Shockwave Medical stock on 29 December 2021 worth over 3,525,000$. On average, Frank trades about 3,306 units every 24 days since 2019. As of 6 March 2024 Frank still owns at least 6,532 units of Shockwave Medical stock.
You can see the complete history of Frank Watkins stock trades at the bottom of the page.
Frank's mailing address filed with the SEC is C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA, CA, 95054.
Over the last 6 years, insiders at Shockwave Medical have traded over 488,603,927$ worth of Shockwave Medical stock and bought 30,000 units worth 510,000$ . The most active insiders traders include James E Deerfield Mgmt L.P....、Antoine Papiernik、Capital Vii Fcpr Sofinnova. On average, Shockwave Medical executives and independent directors trade stock every 8 days with the average trade being worth of 10,693,924$. The most recent stock trade was executed by Trinh Phung on 17 May 2024, trading 19,763 units of SWAV stock currently worth 121,740$.
shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen
Shockwave Medical executives and other stock owners filed with the SEC include: